Abstract Adenosine receptors (ARs) have emerged as new drug targets. The majority of data on affinity/potency and selectivity of AR ligands described in the literature has been obtained for the human species. However, preclinical studies are mostly performed in mouse or rat, and standard AR agonists and antagonists are frequently used for studies in rodents without knowing their selectivity in the investigated species. In the present study, we selected a set of frequently used standard AR ligands, 8 agonists and 16 antagonists, and investigated them in radioligand binding studies at all four AR subtypes, A 1 , A 2A , A 2B , and A 3 , of three species, human, rat, and mouse. Recommended, selective agonists include CCPA (for A 1 AR of rat and mouse), CGS-21680 (for A 2A AR of rat), and Cl-IB-MECA (for A 3 AR of all three species). The functionally selective partial A 2B agonist BAY60-6583 was found to additionally bind to A 1 and A 3 AR and act as an antagonist at both receptor subtypes. The antagonists PSB-36 (A 1 ), preladenant (A 2A ), and PSB-603 (A 2B ) displayed high selectivity in all three investigated species. MRS-1523 acts as a selective A 3 AR antagonist in human and rat, but is only moderately selective in mouse. The comprehensive data presented herein provide a solid basis for selecting suitable AR ligands for biological studies.
Introduction
Although purinergic signaling was proposed as early as 1970, the cloning of these receptors in the early 1990s was a turning point in the acceptance of the purinergic signaling hypothesis [1] . P1 (adenosine) receptors, which are distinguished from P2 (ATP) receptors, comprise four subtypes of G protein-coupled receptors: A 1 , A 2A , A 2B , and A 3 [1, 2] . All adenosine receptors (ARs) are coupled to adenylate cyclase. Whereas A 1 and A 3 ARs inhibit adenylate cyclase, A 2A and A 2B ARs stimulate its activity and thereby increase the intracellular concentration of cAMP [3] . The wide distribution of ARs in virtually all tissues is an indication of their significance and their promising potential as drug targets [4] . The nonselective AR antagonists, caffeine, and theophylline, which are plant-derived alkaloids, have been used as drugs since a long time for various indications, including countering of fatigue and restoration of alertness, treatment of pain (in combination with analgesics), bronchial asthma, chronic obstructive pulmonary disease (COPD), prevention of sleep apnea, and treatment of apnea Electronic supplementary material The online version of this article (doi:10.1007/s11302-015-9460-9) contains supplementary material, which is available to authorized users. in preterm infants [5] . In the past decades, many potent AR agonists and antagonists with selectivity for one of the four subtypes have been developed [5, 6] . Radioligands as well as fluorescent-labeled ligands for ARs have been prepared [7] [8] [9] . The development of new ligands targeting ARs has been facilitated by recently published crystal structures of the A 2A AR bound to both, agonists and antagonists [10] [11] [12] [13] . Several AR agonists and antagonists are currently evaluated in clinical trials or have recently been approved as diagnostic or therapeutic drugs [14, 15] .
The A 1 AR of human, rat, and mouse consists of 326 amino acids. The percentage of amino acid sequence identity of the A 1 AR in the three species was determined to be as follows: human vs. rat 95 %, human vs. mouse 95 %, and rat vs. mouse 98 % (for details see supporting information). (Partial) A 1 AR agonists are clinically developed for cardiologic indications including arrhythmia, atrial fibrillation, and coronary and ventricular dysfunction [16, 17] . Further indications may comprise metabolic syndrome including hyperlipidemia and type II diabetes [18] . A 1 antagonists have been evaluated for the treatment of congestive heart failure and renal failure [19] .
The A 2A AR is the largest AR subtype consisting of 412 amino acids in humans and 410 amino acids in rat and mouse. The percentage of amino acid sequence homology of A 2A AR in the three species was determined to be as follows: human vs. rat 82 %, human vs. mouse 82 %, and rat vs. mouse 96 %. Adenosine (Adenoscan®) and regadenoson (Lexiscan®) are used in myocardial stress imaging acting on A 2A ARs of coronary blood vessels which leads to dilation and a drop in blood pressure [20, 21] . The A 2A AR represents one of the most important regulators of the innate immune response. A 2A ARs inhibit the secretion of proinflammatory mediators by immune cells dampening inflammatory reactions [22, 23] and therefore have potential as anti-inflammatory, anti-rheumatic, and immunosuppressive drugs. Separation of their antiinflammatory and hypotensive effects has recently been achieved by a prodrug approach [24] . A 2A AR antagonists are widely investigated for their role in neurodegenerative diseases like Parkinson's and Alzheimer's disease [25] [26] [27] . The A 2A -selective antagonist istradefylline (NOURIAST®) has recently been approved in Japan for the treatment of Parkinson's disease, and further A 2A AR antagonists are in clinical development [28, 29] .
The A 2B AR consists of 332 amino acids in human, rat, and mouse. The percentage of amino acid sequence homology of A 2B AR in the three species was determined to be as follows: human vs. rat 86 %, human vs. mouse 87 %, and rat vs. mouse 96 %. Preclinical studies indicated a potential of A 2B agonists for the treatment of atherosclerosis and hyperlipidemia [30] . A 2B antagonists may be useful for the treatment of asthma, diabetes, pain, and inflammatory diseases in general, although the A 2B AR has been reported to promote pro-as well as antiinflammatory effects [6, [31] [32] [33] . Furthermore, A 2B antagonists were proposed for the treatment of cancer and the prevention of metastasis [34, 35] .
The A 3 AR consists of 318 amino acids in human, 320 amino acids in rat, and 319 amino acids in mouse. The percentage of amino acid sequence homology of A 3 AR in the three species was determined to be as follows: human vs. rat 73 %, human vs. mouse 73 %, and rat vs. mouse 91 %. A 3 AR agonists are developed for the treatment of rheumatoid arthritis, psoriasis, and other autoimmune diseases [36] . A 3 antagonists may be useful for the treatment of asthma [37] or glaucoma [38] .
Taking the (patho) physiological importance of ARs and their great potential as drug targets into consideration, it is obvious that the question of species differences is pivotal. Since rat and mouse are the most widely employed animals in preclinical studies, it is extremely important to know and consider potential differences in potency and selectivity of the receptor ligands that are applied as pharmacological tools, e.g., for target validation studies. Differences in affinity and potency of several AR ligands at different species have been obvious [39, 40] , especially regarding the A 3 AR subtype. Many A 3 antagonists are highly potent at the human receptor, but only weakly active or inactive at rodent A 3 ARs [5, 41, 42] .
Since the event of receptor cloning and heterologous expression, new compounds are typically evaluated on human receptors, the ultimate target in drug development. However, the first in vivo studies are performed in rodents. Very often, it appears difficult to choose the most suitable subtype-selective AR agonist or antagonist for a specific preclinical in vivo study or to judge the results of such investigations, due to the lack of knowledge about potential species differences regarding the various ligands. This knowledge is essential for tool compounds that are commonly utilized in experimental pharmacology of ARs in order to avoid jumping to false conclusions about their effects and the AR subtypes involved. Surprisingly, we discovered that for many AR agonists and antagonists, that are commonly applied in in vitro and in vivo studies, comprehensive data at all subtypes of human, rat, and mouse ARs are lacking. Especially data for mouse receptors are sparse despite the fact that mice represent the most abundant animal models in drug research. In fact, for many compounds described in the literature, only data at human ARs have been published. Nevertheless, such ligands are frequently used in mouse or rat models without knowing but just assuming that their profiles were identical across species. In the present study, we therefore investigated the most frequently applied standard AR agonists and antagonists in radioligand binding assays at human, mouse, and rat A 1 , A 2A , A 2B , and A 3 AR. Our goal was to determine the compounds' affinities and to calculate their selectivity within each species. Based on the results, suitable ligands for each of the investigated species can then be recommended.
Experimental section Chemicals and compounds
The AR ligands, caffeine, theophylline, NECA, R-PIA, and MRS-1523 were commercially available from Sigma Aldrich. CADO was commercially available from TCI. CCPA, CGS-21680, Cl-IB-MECA, IB-MECA, DPCPX, ZM-241835, and MRS-1745 were commercially available from TOCRIS. BAY60-6583 was kindly provided by Dr. Thomas Krahn (Bayer Healthcare). The following compounds were synthesized in our laboratory according to published procedures: PSB-36 [43] , PSB-63 [43] , PSB-601 [44] , PSB-1115 [45] , PSB-0788 [46] , PSB-603 [46] , istradefylline (KW-6002) [47] , and preladenant (SCH-240814) [48] .
Molecular biology
The cDNAs of rat A 1 (rA 1 ), rA 2A , and mouse A 3 (mA 3 ) were purchased from OriGeneInc. (Rockville, USA) and subcloned into the vector pQCXIN. The cDNAs of the mA 1 , mA 2A , and mA 2B receptor were obtained from ImaGenesInc. (Rockville, USA) and subcloned into the vector pLXSN. All cDNAs were amplified by PCR (initial denaturation for 4 min at 94°C; 25 cycles of 1 min 94°C, 1 min 66°C, and 2 min 72°C; final elongation for 10 min at 72°C) using the primers listed in supplemental Table 1 adding the desired restriction sites necessary for the insertion into the vectors.
The cDNAs of rA 2B and rA 3 were amplified from genomic DNA of PC12 cells. Genomic DNA was isolated using the Purelink TM genomic DNA mini kit (Invitrogen, Darmstadt, Germany), and both exons of the rA 2B and rA 3 genes were amplified separately using the primers listed in supplemental Table 2 with the following PCR protocol: initial denaturation for 4 min at 94°C; 40 cycles of 1 min 94°C, 1 min gradient of 49-62°C, and 1 min 72°C; final elongation for 10 min at 72°C.
The two exons of rA 2B were inserted into the vector pLXSN by sequential ligation. In brief, in a second PCR reaction, the desired restriction sites were added into the 5′ end of exon 1 and the 3′ end of exon 2 using the primer pairs frA 2B -EcoRI/r-rA 2B -Exon1 and f-rA 2B -Exon2/r-rA 2B -BamHI applying the protocol for cloning described above. The digested vector and both exons were then ligated using T4 ligase for 1 h at room temperature followed by heat inactivation of the ligase for 10 min at 65°C. The remaining blunt ends of the two exons were phosphorylated using the T4 protein kinase N for 45 min at 37°C followed by heat inactivation of the enzyme for 15 min at 55°C. The second ligation was carried out at 16°C overnight.
The two exons of rA 3 were combined by overlap extension PCR, and the final product was cloned into pQCXIN as described above. In brief, the exons were amplified in two separate PCR reactions with the primer pairs f-rA 3 /r-rA 3 -Overlap-Ex1 and f-rA 3 -Overlap-Ex2/r-rA 3 , respectively, (see supporting information Table 3 ) using the following protocol: initial denaturation for 4 min at 94°C; 35 cycles of 1 min 94°C, 1 min gradient of 49-57°C, and 1 min 72°C; final elongation for 10 min at 72°C. Both products were mixed and, without adding additional primers, the following PCR protocol was run: initial denaturation for 4 min at 94°C; 10 cycles of 1 min 94°C, 1 min 49°C, and 1 min 72°C; final elongation for 5 min at 72°C. The primers f-rA 3 -EcoRI and r-rA 3 -XhoI (see supporting information Table 2 ) were then added, and the final product, which was used for cloning, was obtained by 35 cycles of the same PCR protocol.
The GP + envAM12 cell line, derived from mouse fibroblasts, was used as a packaging cell line. Then the cDNAs were introduced into Chinese hamster ovary (CHO) cells via retroviral transfection. A cotransfection with a vector encoding the glycoprotein G of the vesicular stomatitis virus (VSV-G) was conducted in order to expand the host range of the retrovirus. Thus, stably transfected cell lines with the desired receptors were established.
Membrane preparation
Membranes of CHO cells expressing the A 1 , A 2A , A 2B , or A 3 receptor were prepared by scratching the cells off the previously frozen cell culture dishes in ice-cold hypotonic buffer (5 mM TRIS, 2 mM EDTA, pH 7.4). The cell suspension was homogenized on ice for 20 s with an Ultra-Turrax and centrifuged for 10 min (4°C) at 1000g in order to get rid of the cell organelles. The supernatant was subsequently centrifuged for 60 min at 48,000g in order to collect the protein pellets. The supernatant was then discarded, and the obtained membrane pellets were resuspended in 0.1 mL per dish of 50 mM TRIS 3 AR as an agonist RL. All saturation assays were carried out in a total volume of 400 μl, with the exception of A 2B assays, which were performed in a total volume of 1000 μl. The radioligand stock solutions were prepared using 50 mM TRIS buffer, pH 7.4 with the exception of the [ 3 H]NECA stock solutions, which were prepared using 50 mM TRIS, 1 mM EDTA, 10 mM MgCl 2 buffer of pH 8.25. For A 1 , A 2A , and A 3 AR, the saturation assays were 10,700 [61] 18,800 [46] 41,000 [62] 50,700±5800 performed by adding 190 μl of the buffer, 10 μl DMSO (total binding), or 10 μl of a specific ligand in DMSO for the nonspecific binding (CADO or DPCPX at a final concentration of 10 μM for agonists, or antagonists at A 1 AR, respectively; NECA or CGS-15943 at a final concentration of 50 μM or 10 μM for agonists or antagonists at A 2A AR, respectively; R-PIA at a final concentration of 100 μM for A 3 AR). The corresponding membrane preparation (100 μl) and 100 μl of the suitable radioligand solution were added. Both saturation and competition assays were performed in the presence of 2 U/ml of adenosine deaminase (ADA). The saturation assays for the A 2B AR were performed by adding 775 μl of the buffer, 25 μl of DMSO (total binding), or 25 μl of DPCPX dissolved in DMSO at a final concentration of 10 μM for non-specific binding, 100 μl of the corresponding membrane preparation, and 100 μl of the radioligand solution.
The incubation was done at room temperature, and the time was 90 min (for agonists) or 60 min (for antagonists) at A 1 ARs, 30 min (for agonists) and 60 min (for antagonists) at A 2A ARs, 75 min at A 2B ARs for both agonists and antagonists, and 180 min at A 3 ARs for both agonists and antagonists.
Competition binding assays
Competition binding assays were performed using the radioligands mentioned above previously characterized in saturation binding assays. 9560 [5] 43,000 [62] 32,500 [46] 11,100±2000 H]NECA, 10 nM. All assays except for the A 2B assays were performed in a final volume of 400 μl containing 190 μl of 50 mM TRIS buffer, pH 7.4, 10 μl of the test compound in DMSO, 100 μl of membrane preparation, and 100 μl of the radioligand. The A 2B assays were performed in a final volume of 1000 μl containing 775 μl of the 50 mM TRIS buffer, pH 7.4, 25 μl of the test compound in DMSO, 100 μl of membrane preparation, and 100 μl of the radioligand. Nonspecific binding was determined using the compounds CADO or DPCPX, NECA or CGS15943, DPCPX, and R-PIA, at final concentration of 10, 50 or 10, 10, and 100 μM for A 1 , A 2A , A 2B , and A 3 ARs, respectively.
The incubation was performed at room temperature for 90 min (agonists) and 60 min (antagonists) at A 1 ARs, 30 min (agonists) and 60 min (antagonists) at A 2A ARs, 75 min at A 2B AR for both agonists and antagonists, and 180 min at A 3 AR for both agonists and antagonists. After the incubation, the assay mixture was filtered through GF/B glass fiber filters using a Brandel harvester (Brandel, Gaithersburg, MD, USA). Filters were washed four times (3-4 ml each) with ice-cold 50 mM Tris-HCl buffer, pH 7.4 (for A 1 , A 2A , and A 3 assays). Filters in the A 2B assays were washed four times (3-4 mL each) with ice-cold 50 mM Tris-HCl buffer, pH 7.4 containing 0.1 % bovine serum albumin (BSA) in order to reduce non-specific binding. Then filters were transferred to scintillation vials, incubated for 9 h with 2.5 mL of scintillation cocktail (Beckmann Coulter), and counted in a liquid scintillation counter (Tricarb 2700TR) with a counting efficiency of~53 %. Three separate experiments in duplicates were performed for each assay.
ß-arrestin recruitment assay
The β-arrestin recruitment assay is based on the detection of the interaction of a GPCR with β-arrestin by β-galactosidase fragment complementation (β-arrestin Path Hunter assay, DiscoverX, Fremont, CA, USA). The GPCR of interest is fused to the Prolink tag, the N-terminal part of β-galactosidase, and β-arrestin is fused to the enzyme acceptor, which is β-galactosidase lacking the first 41 amino acids. Upon receptor activation, β-arrestin is recruited to the receptor which leads to the complementation of both β-galactosidase fragments [71] . The activity of the functional β-galactosidase is measured by chemiluminescence using commercial Path Hunter detection reagents.
Recruitment of β-arrestin molecules to the respective receptor was detected by using β-galactosidase fragment complementation technology (β-arrestin Path Hunter assay, DiscoverX, Fremont, CA, USA). CHO cells stably expressing the respective receptor were seeded in a volume of 90 μL into a 96-well plate and incubated at a density of 20,000 cells/well in the provided plating reagent for 24 h at 37°C. After the incubation, test compounds were diluted in PBS buffer containing 10 % DMSO and 0.1 % BSA and added to the cells in a volume of 10 μL, followed by incubation for 90 min at 37°C. For the determination of baseline luminescence, PBS buffer (containing 10 % DMSO, 0.1 % BSA) in the absence of test compound was used. During the incubation period, the detection reagent was prepared. For the determination of β-arrestin recruitment, the provided detection reagent was used according to the supplier's protocol. After the addition of 50 μL/well detection reagent to the cells, the plate was incubated for an additional 60 min at room temperature. Finally, luminescence was determined in a luminometer (TopCount NXT, Packard/Perkin-Elmer).
For the determination of antagonistic properties of tested compounds, the assay was performed as described for agonists except that the test compounds were added to the cells in a volume of 5 μL/well 60 min prior to addition of the agonist (100 nM CCPA final concentration, corresponding to EC 80 , for A 1 AR; 30 nM Cl-IB-MECA final concentration, corresponding to EC 80 , for A 3 AR). Data were obtained from three independent experiments performed in duplicate. Data were analyzed using Graph Pad Prism, version 4.02 (San Diego, CA, USA).
cAMP accumulation in CHO cells
Cells were removed from a confluent 175-cm 2 flask, transferred into a 50-ml Falcon tube, and centrifuged at 200g, 4°C for 5 min. After removal of the supernatant, the cell pellet was resuspended in DMEM-F12 medium. The cell suspension (500 μl, ∼200,000 cells per well) was transferred to 24-well plates and incubated for 24 h at 37°C. After removal of the culture medium, cells were washed HBSS buffer and then incubated with 230 μl HBSS buffer for 2 h at 37°C. The phosphodiesterase inhibitor Ro20-1724 (final concentration 40 μM) dissolved in 100 % HBSS buffer was added to each well, and the cells were incubated for 10 min. For assaying antagonists, 12.5 μl of antagonist was added to the cells which were subsequently incubated for 10 min, and thereafter 12.5 μl of agonist was added and the cells were incubated again for 10 min. For assaying agonists, 25 μl of the agonist was added and the cells were incubated for 20 min. After incubation with the agonist, cAMP production was stimulated by the addition of forskolin (final concentration 10 μM) for 10 min; the final DMSO concentration did not exceed 1.4 %. The reaction was stopped by the removal of the reaction buffer followed by the addition of a hot lysis buffer (250 μl; 90°C; 4 mM EDTA, 0.01 % Triton X-100; Sigma, Munich, Germany). The 24-well plates were kept at room temperature for 5 min and then kept at −20°C. For competition binding experiments, 50 μl of the cell lysates were transferred into 2.5-ml tubes.
[ 
Data analysis and statistics
The specific binding, which is described as the radioligand binding to a ligand-specific binding site of the respective receptor, was calculated as the difference between total and nonspecific binding. 
Results
For the evaluation of a selection of the most frequently used standard AR agonists and antagonists at human (h), rat (r), and mouse (m) A 1 , A 2A , A 2B , and A 3 ARs recombinant CHO cell lines were employed. Cells expressing the human AR subtypes were previously prepared [46, 49] , and data for standard AR ligands at the human receptors had already been reported in the literature. Cell lines expressing the rat and the mouse AR subtypes were established in the present study.
Cloning and expression of adenosine receptors
The cloning of the following receptor genes was conducted: rA 1 3 H]MSX-2 determined at the mA 2A was 12.1 nM, which is in accordance with results from an autoradiography study using mouse striatum [53] . The B max value of 211 fmol/mg was not high, but similar to that determined by Klotz et al. for the human A 2A AR expressed in CHO cells [49] . To address this problem of only moderate expression of the A 2A AR, the retroviral transfection was repeated and considerably higher specific binding was observed for the new batch indicating a higher expression level. Saturation assays using [
3 H]CGS-21680 at mA 2A ARs provided a K D value of 17.0 nM. The determined B max value of 519 fmol/mg was high enough to efficiently conduct competition radioligand binding assays. It is noteworthy to mention that the expression level of the receptor in the pooled cell line deteriorated quickly after some cell passages. This indicates the need to pick single clones in order to obtain a monoclonal cell line, which can exhibit a high expression level over a long period of time.
Due to the lack of a highly potent agonist A 2B AR radioligand, for A 2B ARs, only the antagonist radioligand [ 3 H]PSB-603 was employed, and its K D value was determined at mA 2B and rA 2B ARs (Figs. 2a, b) . The determined K D values were 4.09 nM for the mA 2B AR and 0.457 nM for the rat A 2B AR. The K D value for the rA 2B AR is similar to the previously determined K D value of 0.403 nM for this radioligand for the human A 2B AR [53] . Interestingly, the K D value for the mA 2B AR was ca. 10-fold higher than that determined for the human and rat orthologues. Borrmann et al. [46] had reported a K D value of 0.35 nM for PSB-603 at the mA 2B AR determined by homologous competition, which is typically less accurate than saturation binding. The B max value for the mA 2B cell line was determined to be 1480 fmol/mg indicating a high expression level. For the rA 2B AR cell line, a B max value of 408 fmol/mg protein was found, which was lower that for the mA 2B AR, but still adequate to perform competition radioligand binding assays.
The non-specific agonist radioligand [ (Figs. 2c, d ). The determined B max values of 6000 fmol/mg protein for the rat and 1840 fmol/mg for the mouse A 3 AR indicated high expression levels of both receptor subtypes. Scatchard transformations of all conducted saturation experiments were calculated (see Supporting Information, Fig. S1 and S2 ).
The results of the saturation binding assays are summarized in Table 1 .
Competition binding assays
A set of eight agonists and 16 antagonists was selected and investigated at the four AR subtypes of the three species, human, rat, and mouse. We picked the most frequently used standard ligands. Further criteria included general availability and subtype-selectivity, although we additionally investigated some non-selective standard ligands, such as NECA, CADO, and caffeine. Figure 3 shows the chemical structures of the selected agonists as well as their AR-subtype selectivity. Structures of the investigated antagonists along with their selectivity are depicted in Fig. 4 .
Before conducting the assays, a systematic search was carried out to find literature K i values for these agonists and antagonists. Data at human ARs for almost all of the selected compounds had previously been published. Our aim was to determine those K i values that had not been previously reported; therefore, we focused our studies on the rodent receptors. The compounds were initially tested at a high concentration of 10 or 1 μM, depending on solubility, and if the K i value was expected to be below 10 μM, full concentration-inhibition curves were recorded. In all cases, three independent experiments were performed, each in duplicates.
A 1 adenosine receptor affinities
Affinities at human and rat A 1 ARs were available for most of the investigated standard ligands; however, affinities for the mouse A 1 AR had to be determined. In Table 2 , literature data and the additional newly determined values are collected.
CCPA was the most potent agonist at mouse and human A 1 ARs displaying subnanomolar affinities. Only at the rat A 1 AR, R-PIA was somewhat more potent than CCPA.
The most potent A 1 agonist at human and rat A 1 ARs was the xanthine derivative PSB-36 displaying subnanomolar affinities. However, at the mA 1 AR, DPCPX was fourfold more potent than PSB-36. Interestingly, some of the most potent compounds at the mA 1 AR were the non-selective antagonist CGS-15943 and the A 2B -selective antagonist MRS-1754 with K i values around 1 nM. MRS-1754 was weaker at the rat and much weaker at the human A 1 AR.
It is also noteworthy that the A 1 -selective antagonists PSB-36 and PSB-63 (see Fig. 4 ) displayed significantly lower affinity at the mouse as compared to the rat A 1 AR. Their affinity for the human A 1 AR, especially that of PSB-63, was also lower at the mouse A 1 AR in comparison with the human A 1 AR. These antagonists were clearly most potent at the rat Table 3 ).
NECA and CGS-21680 were the most potent A 2A agonists in all three species. Both nucleosides showed similar A 2A affinity. Only at the mA 2A receptor NECA was somewhat less potent. The A 2B partial agonist BAY60-6583 was not active at A 2A ARs of the three species.
The selective A 2A antagonists preladenant, ZM-241385 and istradefylline, and the non-selective CGS-15943 were the most potent A 2A antagonists at all three species. Preladenant and CGS-15943 were several-fold more potent at the mouse as compared to the rat and human A 2A AR.
A 2B adenosine receptor affinities
A suitable agonist radioligand for A 2B ARs is currently not available. Therefore, agonists as well as antagonists were investigated using the antagonist radioligand [ 3 H]PSB-603. It should be kept in mind that the affinity of the agonists may be underestimated when using an antagonist radioligand [72] . Results of competition binding assays at A 2B ARs are presented in Table 4. BAY60-6583 showed the highest affinity of all investigated agonists at A 2B ARs of all three species. NECA was severalfold weaker but still one of the most potent A 2B agonists. The higher affinity of BAY60-6583 as compared to NECA may be due to the fact that it is a partial agonist and therefore may show higher affinity than a full agonist when tested versus an antagonist radioligand. Both compounds did not display species differences.
The most potent A 2B antagonists were PSB-603 with subnanomolar affinity at all three species, and its analog PSB-0788, which was similarly potent at the human, but somewhat less potent at rat and mouse A 2B receptors. The A 1 and A 2A antagonists DPCPX, PSB-36, and ZM-241385 also showed relatively high affinity for A 2B ARs. [78] only binds to human A 3 ARs with high affinity but not to rat or mouse A 3 ARs. Binding data at human, rat, and mouse A 3 ARs are collected in Table 5 .
Cl-IB-MECA and IB-MECA were the most potent A 3 AR agonists displaying affinity in the nanomolar to sub-nanomolar range. However, many of the non-A 3 -selective agonists also showed relatively high A 3 -affinity. Interestingly, the partial A 2B agonist BAY60-6583 confirmed the functional selectivity of BAY60-6583 at mA 2B AR using cAMP assays, showing an EC 50 value of 2.83 nM at mA 2B AR and no activation of the other mAR subtypes at concentrations of up to 1 μM [82] . This, together with our data, suggests that BAY60-6583 has a high selectivity only in functional assays but not in Fig. 4 Structures and selectivity of the investigated adenosine receptor antagonists binding studies. BAY60-6583 has recently been shown to act as a partial agonist at A 2B ARs [83] . It may be an antagonist at other AR subtypes, which could be an explanation for the fact that BAY60-6583 was found to lack activation of human A 1 , A 2A , and A 3 AR subtypes, but showed affinity in binding studies. In order to investigate this possibility, β-arrestin assays at hA 1 and hA 3 ARs were conducted. Our results showed no agonism of BAY60-6583 in ß-arrestin translocation assays using β-galactosidase complementation technology (data not shown). However, in the same assays, BAY60-6583 inhibited hA 1 receptor activation by CCPA (100 nM, corresponding to its EC 80 ) with an IC 50 value of 7400 ± 2190 nM; it also blocked hA 3 AR activation by Cl-IB-MECA (30 nM, corresponding to its EC 80 ) with an IC 50 value of 6700±830 nM (see Fig. 5 ). The corresponding K i values for BAY60-6583 were 3190 nM (hA 1 ) and 5630 nM (hA 3 ). Since both, hA 1 and hA 3 , are G icoupled receptors [56] , we additionally performed cAMP accumulation assays after stimulating the cells with forskolin. The effects of 10 μM BAY60-6583 on the concentration-response curves of the agonist NECA were determined at both receptor subtypes. As shown in from cAMP studies were consistent with the data obtained in radioligand binding studies (see Tables 2 and  5 ). K i values determined in β-arrestin arrestin assays were about 10-fold higher. These findings proved that BAY60-6583 can act as a moderately potent antagonist at hA 1 and hA 3 ARs inhibiting G i -as well as β-arrestinmediated signaling. The development of potent antagonists that are similarly potent at human as at rodent A 3 ARs seems to be a formidable challenge. The only antagonists that showed potency at A 3 ARs of all three species were MRS-1523 followed by the non-selective CGS-15934. This could be, at least partially, attributed to the aforementioned significant sequence differences observed for this AR subtype between human and rodent receptors.
The high affinity of the agonist NECA and the lacking affinity, for example, of the antagonist caffeine indicate the importance of the ribose moiety for the binding of ligands to the A 3 AR. A medicinal chemical approach to develop A 3 AR antagonists that are active across species has recently been successfully pursued by Jacobson and coworkers who modified the ribose moiety so that the affinity stayed unaltered but the efficacy disappeared [84] .
Correlations between species
K i values determined for the same compounds in different species were compared, and correlation coefficients were calculated (see Supporting Information for more details). Results are shown in Table 6 and Figs. S7 and S8 (Supporting [70] 113 [70] 519 [70] 1980±150 a Data are means ± SEM of three independent assays performed in duplicates. The values without SEM values are taken from the literature Information). It was found that A 2A ARs and A 2B ARs showed the best correlation among the three species, whereas, as expected, A 3 ARs exhibited the least correlation due to larger differences in receptor sequence.
Discussion
The aim of this study was to determine the affinities of standard agonists and antagonists in the field of AR research at all four receptor AR subtypes of the three species that are of major interest in drug research: human, rat, and mouse. Those data should then lead to recommendations as to which agonist and which antagonist to choose as the most appropriate one for in vitro and in vivo studies in a certain species. A compound was considered selective for one AR subtype versus another if it showed an at least 100-fold preference for one receptor over the others. Based on the collected data, we selected the preferred agonists and antagonists for each AR subtype as discussed below.
The A 1 agonist CCPA
The potency of CCPA is in the nanomolar range at the A 1 AR subtype in all three species, making this compound one of the most potent agonists at this AR subtype. The selectivity versus A 2A and A 2B ARs was high (ca. 10,000-fold). The compound was also selective versus A 3 ARs in rat and mouse, but not highly selective in humans (40-fold) as illustrated in Fig. 6 . Regarding both, potency and selectivity, CCPA seems to be a better choice than R-PIA for use as an A 1 AR agonist in preclinical studies.
The A 1 antagonist PSB-36 PSB-36 is a very potent A 1 AR antagonist with K i values in the nanomolar range in all three species. The selectivity for the A 1 AR was also very high versus the other AR subtypes (at least 400-fold) as shown in Fig. 7 . This makes PSB-36 a powerful, recommended tool compound for blocking the A 1 AR subtype in experimental pharmacological approaches in rat, mouse, and human. It is by far superior to the frequently used A 1 antagonist DPCPX, which shows some affinity for A 2A and A 2B ARs in the three species as well as measurable affinity for the hA 3 AR.
The A 2A agonist CGS-21680 CGS-21680 was the only selective A 2A agonist, which was included in the present study. It showed good affinity for the A 2A AR subtype of the three investigated species. A 2A -selectivity was high versus the A 2B AR, but lower versus the other receptor subtypes. In humans, the A 2A selectivity vs. A 3 was very low (2.5-fold) and moderate vs. A 1 (10-fold). The highest selectivity was observed in rat (>30-fold). CGS-21680 is one of the best available A 2A agonists, but it is only moderately selective. The compound displayed selectivity versus the A 1 AR subtype only in rat. It was not selective versus A 3 ARs in the three species as shown in Fig. 8 . Thus, CGS-21680 is not a very selective A 2A agonist and should therefore be used with care. A study by Linden et al., however, indicated that binding data obtained in recombinant cells might underestimate the potency of A 2A AR agonists due to poor coupling of the receptor to G s protein [85] . Therefore, CGS21680 and other A 2A agonists may display higher selectivity in vivo. However, based on results from binding studies, it is concluded that A 2A agonists with high selectivity across species are currently not available.
The A 2A antagonist preladenant
Preladenant showed the highest potency and selectivity among the investigated A 2A antagonists, it was superior to istradefylline and ZM-241385. This non-xanthine compound, which was evaluated in a phase III clinical trial as an antiParkinsonian drug, but was recently discontinued, may be employed as a very effective antagonist for investigating the A 2A AR subtype in experimental pharmacology. Its affinity is in the (sub) nanomolar range and its selectivity was at least ca. 1000-fold versus all other AR subtypes in the three investigated species (see Fig. 8 ). The A 2A AR antagonist MSX-2 was not included in this study. However, it is a potent, selective, and widely employed antagonist (K i values at A 2A AR are 5.38 and 8.04 nM in human and rat, respectively). In spite of that, its selectivity versus the rA 1 AR (112-fold) is lower than that of preladenant [6] . The A 2B antagonist PSB-603
The high selectivity and affinity of PSB-603 for human and rat A 2B ARs was clearly confirmed. Interestingly, PSB-603 showed an affinity in the micromolar range for the mA 1 AR. Despite that moderate affinity for the mA 1 AR, PSB-603 can still be considered as one of the most suitable antagonists for studying A 2B ARs due to its high affinity and selectivity in all three species. Surprisingly, both BAY60-6583 and PSB-603 showed relatively high affinity for the mouse A 1 AR (Fig. 9) . PSB-603 was found to be superior to the related A 2B antagonist PSB-0788 because the latter exhibited higher affinity for A 2A ARs than PSB-603 and was therefore less selective.
The A 3 agonist Cl-IB-MECA Cl-IB-MECA was superior to IB-MECA concerning both affinity and selectivity. Its affinity for A 3 ARs was in the nanomolar range, and its selectivity versus the A 2A and A 2B AR subtypes was at least 1000-fold. The affinity for the A 1 AR subtype was found to be moderate. Thus, Cl-IB-MECA can be considered as a highly potent and selective A 3 AR agonist in humans, rat, and mouse (see Fig. 10 ).
The A 3 antagonist MRS-1523
Most of the potent A 3 antagonists that have been described show a large preference for the human A 3 receptor and only low or lacking affinity for the rodent A 3 ARs. MRS-1523 is one of the few compounds that had been described to block not only human but also rodent A 3 ARs. Our data show, however, that the compounds' affinity for rat and especially for mouse A 3 ARs is significantly lower than that for the human A 3 AR. Affinity for A 1 and A 2B ARs was found to be low. However, somewhat higher affinities were observed for A 2A ARs in human and rat. This leads to the conclusion that MRS-1523 is not a suitable A 3 antagonist for studies in mice. Its selectivity in rat is also moderate (e.g., fourfold against A 2A ARs). It can only be unreservedly recommended as an A 3 antagonist in humans. But for the human species, much better, more potent, and selective antagonists, e.g., PSB-10, PSB-11, MRE3005-F20, and MRE3008-F20, are available [6] 
Conclusions
In this study, we aimed at investigating the potency and selectivity of selected AR ligands at the four receptor subtypes in human, rat, and mouse using radioligand binding studies. The investigated ligands included 8 agonists and 16 antagonists, which have been widely used in pharmacological and 3 were determined. K i values of the ligands were measured, and a comparison of their affinities and selectivities was conducted to determine the best compound at each receptor subtype. CCPA is the best A 1 agonist of the investigated selection of compounds although its selectivity versus the A 3 subtype is not sufficient. PSB-36 represents the most suitable A 1 antagonist. CGS-21680 is the best A 2A agonist of the tested compounds but its potency and especially its selectivity are moderate. The A 2A antagonist preladenant shows high affinity and an impressive selectivity. Results obtained for the moderately potent A 2B partial agonist BAY60-6583 demonstrated the urgent need to develop better A 2B AR agonists. However, the A 2B antagonist PSB-603 proved to be a very powerful pharmacological tool for studying A 2B receptors concerning both affinity and selectivity. Cl-IB-MECA appears to be a potent and selective agonist at the A 3 subtype. MRS-1523 was found to be the best A 3 antagonist among the investigated compounds for use in rodents, although it is far from being ideal for studies in rats and especially in mice. In contrast, for investigations at human A 3 ARs, much more potent and selective antagonists are available, including PSB-10 and PSB-11, but those compounds are inactive at rodent A 3 ARs. The present study clearly demonstrates that tool compounds have to be comprehensively characterized in the appropriate species before they are used as pharmacological tools in in vitro and in vivo studies. Moreover, concentrations used in in vitro and in vivo studies have to be carefully chosen based on the compounds' affinity and selectivity.
